Kunjali Padhya, MD
Gastroenterology · Seattle, WANPI 1982867560
Payments from drug & device makers
Across 51 payments — averaging $124.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$3K
- Boston Scientific$1K
- Sanofi$366
- 3-d Matrix, Inc.$215
- Enterra Medical, Inc.$167
- AbbVie$162
- plus $862 from 9 others
What the payments were for
- Consulting fees$3,14150%
- Food & beverage$3,18750%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 5 | $3,251 |
| Boston Scientific | 22 | $1,305 |
| Sanofi | 8 | $366 |
| 3-d Matrix, Inc. | 1 | $215 |
| Enterra Medical, Inc. | 1 | $167 |
| AbbVie | 3 | $162 |
| Phathom Pharmaceuticals, Inc. | 1 | $125 |
| Lilly USA, LLC | 1 | $125 |
| Aimmune Therapeutics, Inc. | 1 | $123 |
| Olympus America Inc. | 1 | $116 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $112 |
| ERBE USA Inc | 3 | $83 |
| Gilead | 1 | $67 |
| Cook Medical LLC | 1 | $64 |
| Omega Medical Imaging, LLC | 1 | $46 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$3,411
- EXALT Model D$485
- VOQUEZNA$125
- JARDIANCE$125
- ZENPEP$123
- EXALT MODEL D CONTROLLER$123
- EndoClot PHS$116
- Entyvio$112
- Rinvoq$109
How this compares
$6,328 in reported general payments places this provider in the 80th percentile of 447 gastroenterology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 40 | $2,347 |
| Omeprazole | 61 | $840 |
| Ondansetron OdtOndansetron | 15 | $595 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 36 | $513 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 26 | $407 |
| Dicyclomine Hcl | 19 | $323 |
| Famotidine | 18 | $270 |
| Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl | 16 | $251 |
| Pantoprazole Sodium | 17 | $210 |
| Ondansetron Hcl | 17 | $127 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Seattle
- Kris KowdleySeattle$5.9M
- Scott LeeSeattle$3.7M
- Timothy ZismanSeattle$3.3M
- James LordSeattle$1.9M
- Charles LandisSeattle$1.7M
- Asma SiddiqueSeattle$1.3M
- Karlee AuskSeattle$758K
- Andrew RossSeattle$687K
- Sravanthi ParasaSeattle$485K
- Lei YuSeattle$407K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.